Robert Mayes, Tammy Long, Lacey Huffling, Aaron Reedy, Brad Williamson
Undergraduate Quantitative Biology Impact on Biology Preservice Teachers
Bulletin of mathematical biology
realworld studies concerning different populations valuable bring new information regarding different regimens brolucizumab injections adverse reactions present study investigates efficacy prorenata regimen prn neovascular agerelated macular degeneration namd separate main statistics report use brolucizumab central serous chorioretinopathy csc retrospective observational singlecenter study conducted 82 eyes treated brolucizumab 2021 2023 namd patients injected intervals least 2 months loading phase 9 320 months followup 026 adverse reactions noticed good resolution retinal fluid significant reduction cst sdoct 7250 p 005 especially subretinal fluid 54 eyes remained fluidfree interval injection intoi parameter calculated averaging results division followup period number injections received patient 268 corresponding injection interval 11 weeks could become important parameter characterization brolucizumab antivegf therapy could provide precise interval injection future four patients also received brolucizumab treatment chronic csc 3 doses showed good response 3 remaining fluidfree